WALTHAM, Mass., Feb. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that delays in the U.S.

NEW YORK, Nov.

Future Therapies Modeled After Johnson & Johnson/Basilea's or Forest/Novexel's Drug Could Be Used As First-Line Therapies, According to a New Report from AMR and Decision Resources MALVERN, Pa. and WALTHAM, Mass., Feb.

Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections. Dr.

Basel, Switzerland, October 27, 2008 - Multi-resistant Gram-negative bacteria are causing increasing concern around the world. Basilea's novel antibiotic BAL30072 demonstrates potent in-vitro activity against some of the most difficult to treat multi-resistant Gram-negative bacteria.